<DOC>
	<DOCNO>NCT01092832</DOCNO>
	<brief_summary>The purpose study determine whether voriconazole safe effective treatment serious Candida infection Candida infection esophagus child adolescent .</brief_summary>
	<brief_title>A Study Of The Safety , Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Male female 2 &lt; 18 year age ; Subjects 2 &lt; 12 year age permit enroll study Pfizer sponsor pharmacokinetic study confirms propose dosage correspond age group appropriate . Patients confirm Candida infection blood , body tissue , esophagus . Patient 's doctor feel voriconazole appropriate choice therapy . A known allergy voriconazole azole antifungal drug . Females pregnant , lactate ( breast feed ) plan pregnancy course study , childbearing potential use highly effective method birth control . A patient receiving treatment drug know interfere heart 's electrical system ( QTc prolongation ) . A patient receiving treatment drug permit used voriconazole . For primary therapy : patient receive 48 hour antifungal therapy current episode Candida infection . A patient significant underlying liver disease time enrollment study . A patient significant renal disease ( CrCl &lt; 50 ml/min ) time enrollment study . A patient high likelihood death within 72 hour study enrollment due factor unrelated Candida infection .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Invasive Candidiasis Candidemia Esophageal Candidiasis</keyword>
</DOC>